Ketamine, benzoate, and sarcosine for treating depression.
Study Goal
The researchers aimed to compare the therapeutic mechanisms and efficacy of sarcosine, benzoate, and ketamine derivatives in treating depression by modulating NMDARs and reducing inflammation.
Results Summary
Sarcosine demonstrated efficacy in animal models and human trials by modulating NMDARs and inhibiting microglial activity, suggesting anti-inflammatory and antidepressant effects. It was comparable to other compounds like ketamine and benzoate in its therapeutic potential.
Population
Animal models and human trials (specific population not detailed).
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
sarcosine | decrease | depression | - | - | beneficial therapeutic effects | #1 |
benzoate | decrease | depression | - | - | beneficial therapeutic effects | #2 |
ketamine | decrease | depression | - | - | beneficial therapeutic effects | #3 |
esketamine | decrease | depression | - | - | beneficial therapeutic effects | #4 |
arketamine | decrease | depression | - | - | beneficial therapeutic effects | #5 |
sarcosine, benzoate, and ketamine | neutral | N-methyl-d-aspartate glutamate receptors (NMDARs) | - | - | act by modulating | #6 |
sarcosine, benzoate, and ketamine | decrease | inflammation in the brain | - | - | reducing | #7 |
ketamine, benzoate, and sarcosine | neutral | - | animal models or human trials | - | have demonstrated efficacy | #8 |
sarcosine, benzoate, and ketamine | decrease | microglial activity | in vitro and in vivo studies | - | exert their anti-inflammatory effects by inhibiting | #9 |
sarcosine, benzoate, ketamine, esketamine, and arketamine | decrease | depression | - | - | can be effective in the treatment of | #10 |
Studies have demonstrated the beneficial therapeutic effects of sarcosine, benzoate, and ketamine (including esketamine and arketamine) on depression. These drugs mainly act by modulating N-methyl-d-aspartate glutamate receptors (NMDARs) and reducing inflammation in the brain. Although ketamine, benzoate, and sarcosine act differently as the antagonists or coagonists of NMDARs, they all have demonstrated efficacy in animal models or human trials. In vitro and in vivo studies have indicated that sarcosine, benzoate, and ketamine exert their anti-inflammatory effects by inhibiting microglial activity. This review summarizes and compares the efficacy of the possible therapeutic mechanisms of sarcosine, benzoate, ketamine, esketamine, and arketamine. These compounds act as both NMDAR modulators and anti-inflammatory drugs and thus can be effective in the treatment of depression.